Aligos Therapeutics
ALGS
27 hedge funds and large institutions have $14.7M invested in Aligos Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 24 closing their positions.
52.59% more ownership
Funds ownership: 2.52% → 55.11% (+53%)
11% less capital invested
Capital invested by funds: $16.6M → $14.7M (-$1.9M)
44% less funds holding
Funds holding: 48 → 27 (-21)
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
88% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 24
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$880K |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$337K |
| 3 |
AC
Armistice Capital
New York
|
+$309K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$234K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$605K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$578K |
| 3 |
VVM
Versant Venture Management
San Francisco,
California
|
-$510K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$441K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$321K |
ALGS Hedge Fund Activity: Q3 2024 in Review
27 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q3 2024, worth a combined $14.7M — down 11% from $16.6M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ALGS and 3 opened new positions — a net loss of 21 holders — while 13 trimmed existing stakes and 7 added.
The largest buyer was Woodline Partners, adding an estimated $880K. The largest seller was HHLR Advisors, cutting an estimated $605K.
- 27 institutional investors held Aligos Therapeutics (ALGS) as of Q3 2024, down from 48 in Q2 2024.
- Funds reported $14.7M of Aligos Therapeutics stock for Q3 2024, down 11% quarter-over-quarter.
- 3 funds opened new Aligos Therapeutics positions in Q3 2024 and 24 closed out, a net change of -21 holders.
- The largest Aligos Therapeutics buyer in Q3 2024 was Woodline Partners, an estimated $880K added.
- The largest Aligos Therapeutics seller in Q3 2024 was HHLR Advisors, an estimated $605K sold.
Based on aggregated 13F filings for Q3 2024.